Table 1.

Baseline characteristics and demographic profile of haematological cases with COVID-19

Variable	All patients (n = 242)
Age, years
Median (range)	41(3–83)
Age group, in years; N (%)
> 80   60–80   40–60   18–39   < 18	8(3.3) 60(24.8) 56(23.1) 43(17.8) 75(31)
Sex; N (%)
Female   Male	83(34.3) 159(65.7)
Coexisting co-morbidity (total); N (%)
Cardiovascular disease   Pulmonary disease   Connective tissue   Liver disease   Kidney disease   Diabetes   Non- haematological cancers	68(28.1) 38(15.7) 12(4.9) 4(1.6) 32(13.2) 51(21.1) 04(1.6)
Type of haematological cancer; N(%)
Acute myeloid leukaemia   Acute lymphoblastic leukaemia   Non-Hodgkin’s lymphoma   Hodgkin’s lymphoma   Multiple myeloma   Chronic myeloid leukaemia   CLL   Post stem cell transplant	32(13.2) 85(35.2) 46(19) 4(1.7) 36(14.9) 24(9.9) 7(2.8) 8(3.3)
Time from last chemotherapy for haematological malignancy; N(%)
< 4 weeks   > 4 weeks	116(47.9) 126(52.1)
Status of haematological malignancy at COVID-19 diagnosis; N(%)
Remission   Active disease	94(38.8) 148(61.2)
Blood group
A   B   AB   O	86 (35.5) 84(34.7) 21(8.7) 51(21.1)
COVID-19 symptoms at diagnosis; N(%)
Asymptomatic   Fever   Myalgia   Cough   Dyspnea   Diarrhoea	08(3.3) 209(86.4) 234(96.7) 159(65.7) 87(35.9) 48(19.8)
Anti-cancer therapy; N (%)
Treatment naïve   Chemotherapy   Chemoimmunotherapy   Oral targeted therapy   Immunosuppression only	49(20.2) 124(51.2) 39(16.1) 24(9.9) 06(2.5)
Duration of COVID symptoms at diagnosis; N (%)
< 7 days   ≥ 7 days	70 (28.9) 172(71.1)